AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8869862 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study 1905293 — intervention group
Group type: EXPERIMENTAL
Intervention: Jobs Program (intervention)
Number of subjects: 0
Study 7118065 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg p.o.)
Number of subjects: 0
Study 7118065 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg p.o.)
Number of subjects: 0
Study 31860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to mothers including information on sleep characteristics, improvements in the environment, establishment of a nighttime sleep routine, and waiting before attending nocturnal awakenings.
Number of subjects: 586
Study 31860110 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to mothers.
Number of subjects: 586
Study 31860110 — intervention group
Group type: COMPARATOR
Intervention: Control group received counseling on breastfeeding benefits and written material on breastfeeding.
Number of subjects: 586
Study 28093204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin symphysis bone plus allogeneic bone material plus leukocyte‐ and platelet‐rich fibrin (Group A)
Number of subjects: 20
Study 28093204 — intervention group
Group type: COMPARATOR
Intervention: Iliac bone graft (Group B)
Number of subjects: 20
Study 25005108 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption Guidance Appliance (EGA) for 1 year
Number of subjects: 48
Study 25005108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 48
Study 24256083 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 20 mg/day
Number of subjects: 399
Study 24256083 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 399
Study 24256083 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 100 mg/day
Number of subjects: 399
Study 24256083 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 399
Study 21386714 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24
Study 21386714 — intervention group
Group type: COMPARATOR
Intervention: Medication (control)
Number of subjects: 24
Study 19864243 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN diagnosis reclassification by pathologists
Number of subjects: 1003
Study 19864243 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN diagnosis with threshold at CIN 2
Number of subjects: 1003
Study 19864243 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN diagnosis with threshold at CIN 3
Number of subjects: 1003
Study 19864243 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN 2 diagnosis
Number of subjects: 1003
Study 16979857 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered nursing care (CC)
Number of subjects: 90
Study 16979857 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 90
Study 14688156 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU of recombinant FSH daily and GnRH antagonist Ganirelix 0.25 mg per day
Number of subjects: 66
Study 14688156 — intervention group
Group type: COMPARATOR
Intervention: 50 IU of recombinant FSH on alternate days and GnRH antagonist Ganirelix 0.25 mg per day
Number of subjects: 66
Study 11682380 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.3% in air and oxygen)
Number of subjects: 20
Study 11682380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.0% in air and oxygen)
Number of subjects: 20
Study 11682380 — intervention group
Group type: COMPARATOR
Intervention: Control (Conscious baseline)
Number of subjects: 20
Study 11682380 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressor test sensitivity
Number of subjects: 20
Study 11682380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressor test sensitivity
Number of subjects: 20
Study 9626173 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillator therapy
Number of subjects: 0
Study 9626173 — intervention group
Group type: COMPARATOR
Intervention: Medications alone (Control)
Number of subjects: 0
Study 9626173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous defibrillators (alternative scenario)
Number of subjects: 0
Study 8165081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine emulsion (EMLA)
Number of subjects: 180
Study 8165081 — intervention group
Group type: COMPARATOR
Intervention: Placebo emulsion
Number of subjects: 180
Study 8165081 — intervention group
Group type: COMPARATOR
Intervention: Music distraction
Number of subjects: 180
Study 2835195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate (10 mg)
Number of subjects: 14
Study 2835195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2835195 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study 29412378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes educational program (group education, home visit, telephone intervention)
Number of subjects: 470
Study 29412378 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual monitoring)
Number of subjects: 470
Study 28266949 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine 75 mg + hypnosis (VH)
Number of subjects: 71
Study 28266949 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine 75 mg + sham hypnosis (VSH)
Number of subjects: 71
Study 28266949 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo pill + hypnosis (PH)
Number of subjects: 71
Study 28266949 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo pill + sham hypnosis (PSH)
Number of subjects: 71
Study 26245216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified IFX regimen (n = 36)
Number of subjects: 69
Study 26245216 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment defined by IFX and anti‐IFX antibodies (n = 33)
Number of subjects: 69
Study 23503738 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 87
Study 23503738 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and walking programme
Number of subjects: 87
Study 23503738 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 87
Study 21515591 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerto (automatic left ventricular output management algorithm)
Number of subjects: 739
Study 21515591 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulta (automatic management of atrial, right ventricular and LV voltage)
Number of subjects: 739
Study 21515591 — intervention group
Group type: EXPERIMENTAL
Intervention: Consulta
Number of subjects: 739
Study 21515591 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerto and Consulta
Number of subjects: 739
Study 21515591 — intervention group
Group type: COMPARATOR
Intervention: Sentry (manual voltage adjustments)
Number of subjects: 739
Study 19078952 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA404 plus carboplatin and paclitaxel (ASA404-CP)
Number of subjects: 73
Study 19078952 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 73
Study 16804124 — intervention group
Group type: EXPERIMENTAL
Intervention: Free amino acid solutions
Number of subjects: 0
Study 16804124 — intervention group
Group type: COMPARATOR
Intervention: Standardized oral meal (healthy volunteers)
Number of subjects: 0
Study 14674505 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid 10% followed by 5% NaOCl for 2 minutes
Number of subjects: 0
Study 14674505 — intervention group
Group type: EXPERIMENTAL
Intervention: Maleic acid 10% followed by 5% NaOCl for 2 minutes
Number of subjects: 0
Study 14674505 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% Oxalic acid followed by 5% NaOCl for 2 minutes
Number of subjects: 0
Study 14674505 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% Phosphoric acid followed by 5% NaOCl for 2 minutes
Number of subjects: 0
Study 14674505 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA gel followed by 5% NaOCl for 2 minutes
Number of subjects: 0
Study 14674505 — intervention group
Group type: COMPARATOR
Intervention: Control (no etching agent and/or NaOCl solution)
Number of subjects: 0
Study 11009265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II, n = 208, 254 lesions) for 6 months
Number of subjects: 409
Study 11009265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I, n = 201, 240 lesions) for 1 month
Number of subjects: 409
Study 11009265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II) in diabetic patients
Number of subjects: 409
Study 11009265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I) in diabetic patients
Number of subjects: 409
Study 11009265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol (group II)
Number of subjects: 409
Study 11009265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine (group I)
Number of subjects: 409
Study 8818065 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat Smart School Nutrition Program (CATCH)
Number of subjects: 59
Study 8818065 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 59
Study 1581367 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-enhancement intervention group
Number of subjects: 40
Study 1581367 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment control group
Number of subjects: 40
Study 6146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (150 mg)
Number of subjects: 3
Study 6146180 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 3
Study 6146180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30791871 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention
Number of subjects: 282
Study 30791871 — intervention group
Group type: EXPERIMENTAL
Intervention: Design strategies to maximize recruitment and retention
Number of subjects: 282
Study 28236978 — intervention group
Group type: EXPERIMENTAL
Intervention: Patritumab plus erlotinib
Number of subjects: 212
Study 28236978 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 212
Study 25966781 — intervention group
Group type: COMPARATOR
Intervention: OZ439 alone
Number of subjects: 59
Study 25966781 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ439 plus PQP (800 mg OZ439 with 960 mg PQP)
Number of subjects: 59
Study 25966781 — intervention group
Group type: EXPERIMENTAL
Intervention: OZ439 plus PQP (800 mg OZ439 with 1440 mg PQP)
Number of subjects: 59
Study 25966781 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine
Number of subjects: 59
Study 23680067 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-traffic-light GDA system
Number of subjects: 81
Study 23680067 — intervention group
Group type: COMPARATOR
Intervention: Monochrome GDA system
Number of subjects: 81
Study 21777435 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Patient Information Sheet (PIS)
Number of subjects: 123
Study 21777435 — intervention group
Group type: COMPARATOR
Intervention: Original Patient Information Sheet (PIS)
Number of subjects: 123
Study 21777435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for PIS version
Number of subjects: 123
Study 19304086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric AcrySof SN60WF IOL
Number of subjects: 2
Study 19304086 — intervention group
Group type: COMPARATOR
Intervention: Spherical AcrySof SN60AT IOL
Number of subjects: 2
Study 17236636 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion (TCI) with noxious stimulus (hand immersion in cold water at 2-4 degrees C)
Number of subjects: 20
Study 17236636 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil TCI infusion added to propofol TCI anesthesia
Number of subjects: 20
Study 12771852 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tablets/day for 6 months)
Number of subjects: 150
Study 12771852 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy alone (Control group)
Number of subjects: 150
Study 10950232 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching mothers to provide chloroquine to their sick children at home
Number of subjects: 70
Study 10950232 — intervention group
Group type: COMPARATOR
Intervention: Control group (community health worker approach)
Number of subjects: 70
Study 10950232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 70
Study 10950232 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal autopsy in intervention tabias
Number of subjects: 70
Study 10950232 — intervention group
Group type: COMPARATOR
Intervention: Verbal autopsy in control tabias
Number of subjects: 70
Study 8812724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sodium benzoate (SB) therapy
Number of subjects: 16
Study 1579871 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 92
Study 1579871 — intervention group
Group type: COMPARATOR
Intervention: Conventional disc surgery
Number of subjects: 92
Study 4084669 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol tablets 100 mg, DAK
Number of subjects: 11
Study 4084669 — intervention group
Group type: COMPARATOR
Intervention: Apurin tablets 100 mg, Gea
Number of subjects: 11
Study 31085305 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH response measures
Number of subjects: 488
Study 30205427 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine 2 g
Number of subjects: 22
Study 30205427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 27049809 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% diquafosol tetrasodium ophthalmic solution
Number of subjects: 34
Study 27049809 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 34
Study 24976433 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg as selenomethionine)
Number of subjects: 420
Study 24976433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 23089999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI legume diet
Number of subjects: 121
Study 23089999 — intervention group
Group type: COMPARATOR
Intervention: High wheat fiber diet
Number of subjects: 121
Study 20880348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tungstate (100 mg bid)
Number of subjects: 30
Study 20880348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20880348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tungstate
Number of subjects: 30
Study 18024853 — intervention group
Group type: EXPERIMENTAL
Intervention: GW501516 (10 mg o.d.)
Number of subjects: 18
Study 18024853 — intervention group
Group type: COMPARATOR
Intervention: GW590735 (20 mug o.d.)
Number of subjects: 18
Study 18024853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16005162 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 22
Study 16005162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16005162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 22
Study 16005162 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (50 mg and 25 mg)
Number of subjects: 22
Study 15384293 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-70% nitrous oxide (N2O)
Number of subjects: 22
Study 15384293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2-0.8% sevoflurane
Number of subjects: 22
Study 15384293 — intervention group
Group type: COMPARATOR
Intervention: Both N2O and sevoflurane
Number of subjects: 22
Study 15384293 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% end tidal sevoflurane
Number of subjects: 22
Study 15384293 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O and sevoflurane
Number of subjects: 22
Study 10099142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 253
Study 10099142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 8523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 24
Study 8523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 24
Study 8523053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and Toremifene
Number of subjects: 24
Study 1779028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD)
Number of subjects: 22
Study 1779028 — intervention group
Group type: COMPARATOR
Intervention: Elderly control subjects (EC)
Number of subjects: 22
Study 7015221 — intervention group
Group type: EXPERIMENTAL
Intervention: BW146Y
Number of subjects: 0
Study 7015221 — intervention group
Group type: EXPERIMENTAL
Intervention: BW29Y
Number of subjects: 0
Study 7015221 — intervention group
Group type: COMPARATOR
Intervention: BW146Y and BW29Y
Number of subjects: 0
Study 31204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for malignant lesions
Number of subjects: 2062
Study 31204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for benign lesions
Number of subjects: 2062
Study 31204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for hepatocellular carcinoma
Number of subjects: 2062
Study 31204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for hemangioma
Number of subjects: 2062
Study 31204417 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) for metastases
Number of subjects: 2062
Study 28891777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 140
Study 28891777 — intervention group
Group type: COMPARATOR
Intervention: Behavioral counseling
Number of subjects: 140
Study 26510851 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise: 150 or 300 min/week for five menstrual cycles
Number of subjects: 139
Study 26510851 — intervention group
Group type: COMPARATOR
Intervention: Control group: maintained exercise <75 min/week
Number of subjects: 139
Study 23930552 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided perceptual-training group (n = 9)
Number of subjects: 28
Study 23930552 — intervention group
Group type: COMPARATOR
Intervention: Unguided perceptual-training group (n = 10)
Number of subjects: 28
Study 23930552 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 28
Study 21893709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor plus mobile phone
Number of subjects: 0
Study 21893709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor-only
Number of subjects: 0
Study 21893709 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 19218306 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200
Study 19218306 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 200
Study 17868721 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index in androgen dependent disease
Number of subjects: 1677
Study 17868721 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing body mass index in androgen dependent disease
Number of subjects: 1677
Study 17868721 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index in androgen independent disease
Number of subjects: 1677
Study 19753736 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 60
Study 19753736 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen
Number of subjects: 60
Study 10608651 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Virtual Environment (VE) participation
Number of subjects: 48
Study 10608651 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Virtual Environment (VE) participation
Number of subjects: 48
Study 10608651 — intervention group
Group type: COMPARATOR
Intervention: Passive control participation
Number of subjects: 48
Study 7851592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Percoll separation
Number of subjects: 30
Study 7851592 — intervention group
Group type: COMPARATOR
Intervention: Direct swim-up separation
Number of subjects: 30
Study 7851592 — intervention group
Group type: COMPARATOR
Intervention: SpermPrep filtration column
Number of subjects: 30
Study 1942422 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1200 mg daily (protocol 016)
Number of subjects: 2048
Study 1942422 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 500 mg daily (protocol 019)
Number of subjects: 2048
Study 1942422 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine 1500 mg daily (protocol 019)
Number of subjects: 2048
Study 1942422 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (any dosage)
Number of subjects: 2048
Study 1942422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2048
Study 6791868 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Prep liquid with colonic washout
Number of subjects: 60
Study 6791868 — intervention group
Group type: COMPARATOR
Intervention: Oral mannitol alone
Number of subjects: 60
Study 6791868 — intervention group
Group type: COMPARATOR
Intervention: Oral mannitol with colonic washout
Number of subjects: 60
Study 31711752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-H0731 100 mg
Number of subjects: 69
Study 31711752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-H0731 200 mg
Number of subjects: 69
Study 31711752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-H0731 300 mg
Number of subjects: 69
Study 31711752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-H0731 (various doses)
Number of subjects: 69
Study 31711752 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI-H0731
Number of subjects: 69
Study 31711752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30968678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lertal + standard treatment
Number of subjects: 146
Study 30968678 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard treatment
Number of subjects: 146
Study 28660990 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (Michigan splint) for 30 days
Number of subjects: 39